Does interleukin-35 mediate mucosal immune responses that protect against T-cell-dependent colitis?
IL-35 controls the development of T-cell-dependent colitis in mice. It might be developed as a therapeutic target for patients with chronic intestinal inflammation.
These results suggest that Wnt3a can effectively promote the differentiation of hUCMSCs into epidermal-like cells.